Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Colorectal Cancer

A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
A Randomized, Open-label Study Comparing Adjuvant Chemotherapy With Xeloda, or 5-fluorouracil Plus Leucovorin, on Disease-free and Overall Survival in Patients Who Have Had Surgery for Colon Cancer
Status: Enrolling
Updated:  12/1/2015
Clinical Research Facility
mi
from
Fountain Valley, CA
A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
A Randomized, Open-label Study Comparing Adjuvant Chemotherapy With Xeloda, or 5-fluorouracil Plus Leucovorin, on Disease-free and Overall Survival in Patients Who Have Had Surgery for Colon Cancer
Status: Enrolling
Updated: 12/1/2015
Clinical Research Facility
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
A Randomized, Open-label Study Comparing Adjuvant Chemotherapy With Xeloda, or 5-fluorouracil Plus Leucovorin, on Disease-free and Overall Survival in Patients Who Have Had Surgery for Colon Cancer
Status: Enrolling
Updated:  12/1/2015
Clinical Research Facility
mi
from
Los Angeles, CA
A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
A Randomized, Open-label Study Comparing Adjuvant Chemotherapy With Xeloda, or 5-fluorouracil Plus Leucovorin, on Disease-free and Overall Survival in Patients Who Have Had Surgery for Colon Cancer
Status: Enrolling
Updated: 12/1/2015
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
A Randomized, Open-label Study Comparing Adjuvant Chemotherapy With Xeloda, or 5-fluorouracil Plus Leucovorin, on Disease-free and Overall Survival in Patients Who Have Had Surgery for Colon Cancer
Status: Enrolling
Updated:  12/1/2015
Clinical Research Facility
mi
from
Hartford, CT
A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
A Randomized, Open-label Study Comparing Adjuvant Chemotherapy With Xeloda, or 5-fluorouracil Plus Leucovorin, on Disease-free and Overall Survival in Patients Who Have Had Surgery for Colon Cancer
Status: Enrolling
Updated: 12/1/2015
Clinical Research Facility
mi
from
Hartford, CT
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
A Randomized, Open-label Study Comparing Adjuvant Chemotherapy With Xeloda, or 5-fluorouracil Plus Leucovorin, on Disease-free and Overall Survival in Patients Who Have Had Surgery for Colon Cancer
Status: Enrolling
Updated:  12/1/2015
Clinical Research Facility
mi
from
Miami, FL
A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
A Randomized, Open-label Study Comparing Adjuvant Chemotherapy With Xeloda, or 5-fluorouracil Plus Leucovorin, on Disease-free and Overall Survival in Patients Who Have Had Surgery for Colon Cancer
Status: Enrolling
Updated: 12/1/2015
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
A Randomized, Open-label Study Comparing Adjuvant Chemotherapy With Xeloda, or 5-fluorouracil Plus Leucovorin, on Disease-free and Overall Survival in Patients Who Have Had Surgery for Colon Cancer
Status: Enrolling
Updated:  12/1/2015
Clinical Research Facility
mi
from
Decatur, GA
A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
A Randomized, Open-label Study Comparing Adjuvant Chemotherapy With Xeloda, or 5-fluorouracil Plus Leucovorin, on Disease-free and Overall Survival in Patients Who Have Had Surgery for Colon Cancer
Status: Enrolling
Updated: 12/1/2015
Clinical Research Facility
mi
from
Decatur, GA
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
A Randomized, Open-label Study Comparing Adjuvant Chemotherapy With Xeloda, or 5-fluorouracil Plus Leucovorin, on Disease-free and Overall Survival in Patients Who Have Had Surgery for Colon Cancer
Status: Enrolling
Updated:  12/1/2015
Clinical Research Facility
mi
from
Columbia, MO
A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
A Randomized, Open-label Study Comparing Adjuvant Chemotherapy With Xeloda, or 5-fluorouracil Plus Leucovorin, on Disease-free and Overall Survival in Patients Who Have Had Surgery for Colon Cancer
Status: Enrolling
Updated: 12/1/2015
Clinical Research Facility
mi
from
Columbia, MO
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
A Randomized, Open-label Study Comparing Adjuvant Chemotherapy With Xeloda, or 5-fluorouracil Plus Leucovorin, on Disease-free and Overall Survival in Patients Who Have Had Surgery for Colon Cancer
Status: Enrolling
Updated:  12/1/2015
Clinical Research Facility
mi
from
St Louis, MO
A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
A Randomized, Open-label Study Comparing Adjuvant Chemotherapy With Xeloda, or 5-fluorouracil Plus Leucovorin, on Disease-free and Overall Survival in Patients Who Have Had Surgery for Colon Cancer
Status: Enrolling
Updated: 12/1/2015
Clinical Research Facility
mi
from
St Louis, MO
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
A Randomized, Open-label Study Comparing Adjuvant Chemotherapy With Xeloda, or 5-fluorouracil Plus Leucovorin, on Disease-free and Overall Survival in Patients Who Have Had Surgery for Colon Cancer
Status: Enrolling
Updated:  12/1/2015
Clinical Research Facility
mi
from
Albany, NY
A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
A Randomized, Open-label Study Comparing Adjuvant Chemotherapy With Xeloda, or 5-fluorouracil Plus Leucovorin, on Disease-free and Overall Survival in Patients Who Have Had Surgery for Colon Cancer
Status: Enrolling
Updated: 12/1/2015
Clinical Research Facility
mi
from
Albany, NY
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
A Randomized, Open-label Study Comparing Adjuvant Chemotherapy With Xeloda, or 5-fluorouracil Plus Leucovorin, on Disease-free and Overall Survival in Patients Who Have Had Surgery for Colon Cancer
Status: Enrolling
Updated:  12/1/2015
Clinical Research Facility
mi
from
Buffalo, NY
A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
A Randomized, Open-label Study Comparing Adjuvant Chemotherapy With Xeloda, or 5-fluorouracil Plus Leucovorin, on Disease-free and Overall Survival in Patients Who Have Had Surgery for Colon Cancer
Status: Enrolling
Updated: 12/1/2015
Clinical Research Facility
mi
from
Buffalo, NY
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
A Randomized, Open-label Study Comparing Adjuvant Chemotherapy With Xeloda, or 5-fluorouracil Plus Leucovorin, on Disease-free and Overall Survival in Patients Who Have Had Surgery for Colon Cancer
Status: Enrolling
Updated:  12/1/2015
Clinical Research Facility
mi
from
Cleveland, OH
A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
A Randomized, Open-label Study Comparing Adjuvant Chemotherapy With Xeloda, or 5-fluorouracil Plus Leucovorin, on Disease-free and Overall Survival in Patients Who Have Had Surgery for Colon Cancer
Status: Enrolling
Updated: 12/1/2015
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
A Randomized, Open-label Study Comparing Adjuvant Chemotherapy With Xeloda, or 5-fluorouracil Plus Leucovorin, on Disease-free and Overall Survival in Patients Who Have Had Surgery for Colon Cancer
Status: Enrolling
Updated:  12/1/2015
Clinical Research Facility
mi
from
Philadelphia, PA
A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
A Randomized, Open-label Study Comparing Adjuvant Chemotherapy With Xeloda, or 5-fluorouracil Plus Leucovorin, on Disease-free and Overall Survival in Patients Who Have Had Surgery for Colon Cancer
Status: Enrolling
Updated: 12/1/2015
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
A Randomized, Open-label Study Comparing Adjuvant Chemotherapy With Xeloda, or 5-fluorouracil Plus Leucovorin, on Disease-free and Overall Survival in Patients Who Have Had Surgery for Colon Cancer
Status: Enrolling
Updated:  12/1/2015
Clinical Research Facility
mi
from
Nashville, TN
A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
A Randomized, Open-label Study Comparing Adjuvant Chemotherapy With Xeloda, or 5-fluorouracil Plus Leucovorin, on Disease-free and Overall Survival in Patients Who Have Had Surgery for Colon Cancer
Status: Enrolling
Updated: 12/1/2015
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
A Randomized, Open-label Study Comparing Adjuvant Chemotherapy With Xeloda, or 5-fluorouracil Plus Leucovorin, on Disease-free and Overall Survival in Patients Who Have Had Surgery for Colon Cancer
Status: Enrolling
Updated:  12/1/2015
Clinical Research Facility
mi
from
Austin, TX
A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
A Randomized, Open-label Study Comparing Adjuvant Chemotherapy With Xeloda, or 5-fluorouracil Plus Leucovorin, on Disease-free and Overall Survival in Patients Who Have Had Surgery for Colon Cancer
Status: Enrolling
Updated: 12/1/2015
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
A Randomized, Open-label Study Comparing Adjuvant Chemotherapy With Xeloda, or 5-fluorouracil Plus Leucovorin, on Disease-free and Overall Survival in Patients Who Have Had Surgery for Colon Cancer
Status: Enrolling
Updated:  12/1/2015
Clinical Research Facility
mi
from
Tyler, TX
A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
A Randomized, Open-label Study Comparing Adjuvant Chemotherapy With Xeloda, or 5-fluorouracil Plus Leucovorin, on Disease-free and Overall Survival in Patients Who Have Had Surgery for Colon Cancer
Status: Enrolling
Updated: 12/1/2015
Clinical Research Facility
mi
from
Tyler, TX
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
A Randomized, Open-label Study Comparing Adjuvant Chemotherapy With Xeloda, or 5-fluorouracil Plus Leucovorin, on Disease-free and Overall Survival in Patients Who Have Had Surgery for Colon Cancer
Status: Enrolling
Updated:  12/1/2015
Clinical Research Facility
mi
from
Seattle, WA
A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
A Randomized, Open-label Study Comparing Adjuvant Chemotherapy With Xeloda, or 5-fluorouracil Plus Leucovorin, on Disease-free and Overall Survival in Patients Who Have Had Surgery for Colon Cancer
Status: Enrolling
Updated: 12/1/2015
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
A Randomized, Open-label Study Comparing Adjuvant Chemotherapy With Xeloda, or 5-fluorouracil Plus Leucovorin, on Disease-free and Overall Survival in Patients Who Have Had Surgery for Colon Cancer
Status: Enrolling
Updated:  12/1/2015
mi
from
Buenos Aires,
A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
A Randomized, Open-label Study Comparing Adjuvant Chemotherapy With Xeloda, or 5-fluorouracil Plus Leucovorin, on Disease-free and Overall Survival in Patients Who Have Had Surgery for Colon Cancer
Status: Enrolling
Updated: 12/1/2015
mi
from
Buenos Aires,
Click here to add this to my saved trials
Immune Response in Peripheral Blood of Patients With Colon Cancer
Immune Studies of Peripheral Blood From Patients With Malignant Disease Gastrointestinal Tract
Status: Enrolling
Updated:  12/2/2015
Arizona Cancer Center at University of Arizona Health Sciences Center
mi
from
Tucson, AZ
Immune Response in Peripheral Blood of Patients With Colon Cancer
Immune Studies of Peripheral Blood From Patients With Malignant Disease Gastrointestinal Tract
Status: Enrolling
Updated: 12/2/2015
Arizona Cancer Center at University of Arizona Health Sciences Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Irinotecan and Cetuximab for Colorectal Cancer as Second Line Therapy
A Phase 2 Study of Irinotecan and Cetuximab on an Every 2 Week Schedule, as Second Line Therapy in Patients With Advanced Colorectal Cancer
Status: Enrolling
Updated:  12/2/2015
UPMC Cancer Centers
mi
from
Pittsburgh, PA
Irinotecan and Cetuximab for Colorectal Cancer as Second Line Therapy
A Phase 2 Study of Irinotecan and Cetuximab on an Every 2 Week Schedule, as Second Line Therapy in Patients With Advanced Colorectal Cancer
Status: Enrolling
Updated: 12/2/2015
UPMC Cancer Centers
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Randomized Controlled Trial of Tailored Interactive Multimedia to Reduce Colorectal Cancer Screening Disparities
Randomized Controlled Trial of Tailored Interactive Multimedia to Reduce Colorectal Cancer Screening Disparities
Status: Enrolling
Updated:  12/2/2015
University of California at Davis Health System
mi
from
Sacramento, CA
Randomized Controlled Trial of Tailored Interactive Multimedia to Reduce Colorectal Cancer Screening Disparities
Randomized Controlled Trial of Tailored Interactive Multimedia to Reduce Colorectal Cancer Screening Disparities
Status: Enrolling
Updated: 12/2/2015
University of California at Davis Health System
mi
from
Sacramento, CA
Click here to add this to my saved trials
Randomized Controlled Trial of Tailored Interactive Multimedia to Reduce Colorectal Cancer Screening Disparities
Randomized Controlled Trial of Tailored Interactive Multimedia to Reduce Colorectal Cancer Screening Disparities
Status: Enrolling
Updated:  12/2/2015
University of Colorado
mi
from
Aurora, CO
Randomized Controlled Trial of Tailored Interactive Multimedia to Reduce Colorectal Cancer Screening Disparities
Randomized Controlled Trial of Tailored Interactive Multimedia to Reduce Colorectal Cancer Screening Disparities
Status: Enrolling
Updated: 12/2/2015
University of Colorado
mi
from
Aurora, CO
Click here to add this to my saved trials
Randomized Controlled Trial of Tailored Interactive Multimedia to Reduce Colorectal Cancer Screening Disparities
Randomized Controlled Trial of Tailored Interactive Multimedia to Reduce Colorectal Cancer Screening Disparities
Status: Enrolling
Updated:  12/2/2015
Sophie Davis School of Biomedical Education, City University of New York
mi
from
New York City, NY
Randomized Controlled Trial of Tailored Interactive Multimedia to Reduce Colorectal Cancer Screening Disparities
Randomized Controlled Trial of Tailored Interactive Multimedia to Reduce Colorectal Cancer Screening Disparities
Status: Enrolling
Updated: 12/2/2015
Sophie Davis School of Biomedical Education, City University of New York
mi
from
New York City, NY
Click here to add this to my saved trials
Randomized Controlled Trial of Tailored Interactive Multimedia to Reduce Colorectal Cancer Screening Disparities
Randomized Controlled Trial of Tailored Interactive Multimedia to Reduce Colorectal Cancer Screening Disparities
Status: Enrolling
Updated:  12/2/2015
University of Rochester School of Medicine and Dentistry
mi
from
Rochester, NY
Randomized Controlled Trial of Tailored Interactive Multimedia to Reduce Colorectal Cancer Screening Disparities
Randomized Controlled Trial of Tailored Interactive Multimedia to Reduce Colorectal Cancer Screening Disparities
Status: Enrolling
Updated: 12/2/2015
University of Rochester School of Medicine and Dentistry
mi
from
Rochester, NY
Click here to add this to my saved trials
Randomized Controlled Trial of Tailored Interactive Multimedia to Reduce Colorectal Cancer Screening Disparities
Randomized Controlled Trial of Tailored Interactive Multimedia to Reduce Colorectal Cancer Screening Disparities
Status: Enrolling
Updated:  12/2/2015
University of Texas Health Sciences Center
mi
from
San Antonio, TX
Randomized Controlled Trial of Tailored Interactive Multimedia to Reduce Colorectal Cancer Screening Disparities
Randomized Controlled Trial of Tailored Interactive Multimedia to Reduce Colorectal Cancer Screening Disparities
Status: Enrolling
Updated: 12/2/2015
University of Texas Health Sciences Center
mi
from
San Antonio, TX
Click here to add this to my saved trials
Prevalence and Topography of Adenomas in 40-49 Year Old Patients With a Family History of Colon Cancer
Prevalence and Topography of Adenomas in 40-49 Year Old Patients With a Family History of Colon Cancer
Status: Enrolling
Updated:  12/3/2015
Walter Reed National Military Medical Center
mi
from
Bethesda, MD
Prevalence and Topography of Adenomas in 40-49 Year Old Patients With a Family History of Colon Cancer
Prevalence and Topography of Adenomas in 40-49 Year Old Patients With a Family History of Colon Cancer
Status: Enrolling
Updated: 12/3/2015
Walter Reed National Military Medical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
Prevalence and Topography of Adenomas in 40-49 Year Old Patients With a Family History of Colon Cancer
Prevalence and Topography of Adenomas in 40-49 Year Old Patients With a Family History of Colon Cancer
Status: Enrolling
Updated:  12/3/2015
Ann Arbor VA Healthcare System
mi
from
Ann Arbor, MI
Prevalence and Topography of Adenomas in 40-49 Year Old Patients With a Family History of Colon Cancer
Prevalence and Topography of Adenomas in 40-49 Year Old Patients With a Family History of Colon Cancer
Status: Enrolling
Updated: 12/3/2015
Ann Arbor VA Healthcare System
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Prevalence and Topography of Adenomas in 40-49 Year Old Patients With a Family History of Colon Cancer
Prevalence and Topography of Adenomas in 40-49 Year Old Patients With a Family History of Colon Cancer
Status: Enrolling
Updated:  12/3/2015
University of Michigan
mi
from
Ann Arbor, MI
Prevalence and Topography of Adenomas in 40-49 Year Old Patients With a Family History of Colon Cancer
Prevalence and Topography of Adenomas in 40-49 Year Old Patients With a Family History of Colon Cancer
Status: Enrolling
Updated: 12/3/2015
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Prevalence and Topography of Adenomas in 40-49 Year Old Patients With a Family History of Colon Cancer
Prevalence and Topography of Adenomas in 40-49 Year Old Patients With a Family History of Colon Cancer
Status: Enrolling
Updated:  12/3/2015
John D. Dingell VA Medical Center
mi
from
Detroit, MI
Prevalence and Topography of Adenomas in 40-49 Year Old Patients With a Family History of Colon Cancer
Prevalence and Topography of Adenomas in 40-49 Year Old Patients With a Family History of Colon Cancer
Status: Enrolling
Updated: 12/3/2015
John D. Dingell VA Medical Center
mi
from
Detroit, MI
Click here to add this to my saved trials
Prevalence and Topography of Adenomas in 40-49 Year Old Patients With a Family History of Colon Cancer
Prevalence and Topography of Adenomas in 40-49 Year Old Patients With a Family History of Colon Cancer
Status: Enrolling
Updated:  12/3/2015
Durham VA Medical Center
mi
from
Durham, NC
Prevalence and Topography of Adenomas in 40-49 Year Old Patients With a Family History of Colon Cancer
Prevalence and Topography of Adenomas in 40-49 Year Old Patients With a Family History of Colon Cancer
Status: Enrolling
Updated: 12/3/2015
Durham VA Medical Center
mi
from
Durham, NC
Click here to add this to my saved trials
Prevalence and Topography of Adenomas in 40-49 Year Old Patients With a Family History of Colon Cancer
Prevalence and Topography of Adenomas in 40-49 Year Old Patients With a Family History of Colon Cancer
Status: Enrolling
Updated:  12/3/2015
Huron Gastro
mi
from
Ypsilanti, MI
Prevalence and Topography of Adenomas in 40-49 Year Old Patients With a Family History of Colon Cancer
Prevalence and Topography of Adenomas in 40-49 Year Old Patients With a Family History of Colon Cancer
Status: Enrolling
Updated: 12/3/2015
Huron Gastro
mi
from
Ypsilanti, MI
Click here to add this to my saved trials
Optimization of the Bowel Preparation Regimen for the PillCam COLON 2 Capsule Endoscopy Procedure
MA-205 / COVGIC20482: A Multicenter, Consecutive, Randomized Study to Optimize the Bowel Preparation Regimen for the PillCam COLON 2 Capsule Endoscopy Procedure
Status: Enrolling
Updated:  12/3/2015
Pinnacle Research Group, LLC
mi
from
Anniston, AL
Optimization of the Bowel Preparation Regimen for the PillCam COLON 2 Capsule Endoscopy Procedure
MA-205 / COVGIC20482: A Multicenter, Consecutive, Randomized Study to Optimize the Bowel Preparation Regimen for the PillCam COLON 2 Capsule Endoscopy Procedure
Status: Enrolling
Updated: 12/3/2015
Pinnacle Research Group, LLC
mi
from
Anniston, AL
Click here to add this to my saved trials
Optimization of the Bowel Preparation Regimen for the PillCam COLON 2 Capsule Endoscopy Procedure
MA-205 / COVGIC20482: A Multicenter, Consecutive, Randomized Study to Optimize the Bowel Preparation Regimen for the PillCam COLON 2 Capsule Endoscopy Procedure
Status: Enrolling
Updated:  12/3/2015
Indianapolis Gastroenterology & Hepatology, Inc.
mi
from
Indianapolis, IN
Optimization of the Bowel Preparation Regimen for the PillCam COLON 2 Capsule Endoscopy Procedure
MA-205 / COVGIC20482: A Multicenter, Consecutive, Randomized Study to Optimize the Bowel Preparation Regimen for the PillCam COLON 2 Capsule Endoscopy Procedure
Status: Enrolling
Updated: 12/3/2015
Indianapolis Gastroenterology & Hepatology, Inc.
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Optimization of the Bowel Preparation Regimen for the PillCam COLON 2 Capsule Endoscopy Procedure
MA-205 / COVGIC20482: A Multicenter, Consecutive, Randomized Study to Optimize the Bowel Preparation Regimen for the PillCam COLON 2 Capsule Endoscopy Procedure
Status: Enrolling
Updated:  12/3/2015
Dayton Gastroenterology, Inc.
mi
from
Dayton, OH
Optimization of the Bowel Preparation Regimen for the PillCam COLON 2 Capsule Endoscopy Procedure
MA-205 / COVGIC20482: A Multicenter, Consecutive, Randomized Study to Optimize the Bowel Preparation Regimen for the PillCam COLON 2 Capsule Endoscopy Procedure
Status: Enrolling
Updated: 12/3/2015
Dayton Gastroenterology, Inc.
mi
from
Dayton, OH
Click here to add this to my saved trials
Optimization of the Bowel Preparation Regimen for the PillCam COLON 2 Capsule Endoscopy Procedure
MA-205 / COVGIC20482: A Multicenter, Consecutive, Randomized Study to Optimize the Bowel Preparation Regimen for the PillCam COLON 2 Capsule Endoscopy Procedure
Status: Enrolling
Updated:  12/3/2015
Thomas Jefferson University
mi
from
Philadelphia, PA
Optimization of the Bowel Preparation Regimen for the PillCam COLON 2 Capsule Endoscopy Procedure
MA-205 / COVGIC20482: A Multicenter, Consecutive, Randomized Study to Optimize the Bowel Preparation Regimen for the PillCam COLON 2 Capsule Endoscopy Procedure
Status: Enrolling
Updated: 12/3/2015
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Optimization of the Bowel Preparation Regimen for the PillCam COLON 2 Capsule Endoscopy Procedure
MA-205 / COVGIC20482: A Multicenter, Consecutive, Randomized Study to Optimize the Bowel Preparation Regimen for the PillCam COLON 2 Capsule Endoscopy Procedure
Status: Enrolling
Updated:  12/3/2015
Franklin Gastroenterology
mi
from
Franklin, TN
Optimization of the Bowel Preparation Regimen for the PillCam COLON 2 Capsule Endoscopy Procedure
MA-205 / COVGIC20482: A Multicenter, Consecutive, Randomized Study to Optimize the Bowel Preparation Regimen for the PillCam COLON 2 Capsule Endoscopy Procedure
Status: Enrolling
Updated: 12/3/2015
Franklin Gastroenterology
mi
from
Franklin, TN
Click here to add this to my saved trials
Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors
A Pilot Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors (I-CREST)
Status: Enrolling
Updated:  12/8/2015
Western Regional Medical Center, Inc
mi
from
Goodyear, AZ
Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors
A Pilot Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors (I-CREST)
Status: Enrolling
Updated: 12/8/2015
Western Regional Medical Center, Inc
mi
from
Goodyear, AZ
Click here to add this to my saved trials
A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer
A 2x2 Factorial Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) ("XELOX") With/Without Intravenous Bevacizumab (Q3W) Versus Bolus and Continuous Infusion Fluorouracil/Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) ("FOLFOX-4") With/Without Intravenous Bevacizumab (Q2W) as First-line Treatment for Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  12/11/2015
Clinical Research Facility
mi
from
Berkeley, CA
A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer
A 2x2 Factorial Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) ("XELOX") With/Without Intravenous Bevacizumab (Q3W) Versus Bolus and Continuous Infusion Fluorouracil/Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) ("FOLFOX-4") With/Without Intravenous Bevacizumab (Q2W) as First-line Treatment for Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 12/11/2015
Clinical Research Facility
mi
from
Berkeley, CA
Click here to add this to my saved trials
A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer
A 2x2 Factorial Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) ("XELOX") With/Without Intravenous Bevacizumab (Q3W) Versus Bolus and Continuous Infusion Fluorouracil/Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) ("FOLFOX-4") With/Without Intravenous Bevacizumab (Q2W) as First-line Treatment for Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  12/11/2015
Clinical Research Facility
mi
from
Fountain Valley, CA
A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer
A 2x2 Factorial Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) ("XELOX") With/Without Intravenous Bevacizumab (Q3W) Versus Bolus and Continuous Infusion Fluorouracil/Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) ("FOLFOX-4") With/Without Intravenous Bevacizumab (Q2W) as First-line Treatment for Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 12/11/2015
Clinical Research Facility
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer
A 2x2 Factorial Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) ("XELOX") With/Without Intravenous Bevacizumab (Q3W) Versus Bolus and Continuous Infusion Fluorouracil/Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) ("FOLFOX-4") With/Without Intravenous Bevacizumab (Q2W) as First-line Treatment for Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  12/11/2015
Clinical Research Facility
mi
from
Fullerton, CA
A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer
A 2x2 Factorial Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) ("XELOX") With/Without Intravenous Bevacizumab (Q3W) Versus Bolus and Continuous Infusion Fluorouracil/Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) ("FOLFOX-4") With/Without Intravenous Bevacizumab (Q2W) as First-line Treatment for Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 12/11/2015
Clinical Research Facility
mi
from
Fullerton, CA
Click here to add this to my saved trials
A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer
A 2x2 Factorial Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) ("XELOX") With/Without Intravenous Bevacizumab (Q3W) Versus Bolus and Continuous Infusion Fluorouracil/Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) ("FOLFOX-4") With/Without Intravenous Bevacizumab (Q2W) as First-line Treatment for Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  12/11/2015
Clinical Research Facility
mi
from
Gilroy, CA
A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer
A 2x2 Factorial Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) ("XELOX") With/Without Intravenous Bevacizumab (Q3W) Versus Bolus and Continuous Infusion Fluorouracil/Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) ("FOLFOX-4") With/Without Intravenous Bevacizumab (Q2W) as First-line Treatment for Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 12/11/2015
Clinical Research Facility
mi
from
Gilroy, CA
Click here to add this to my saved trials
A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer
A 2x2 Factorial Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) ("XELOX") With/Without Intravenous Bevacizumab (Q3W) Versus Bolus and Continuous Infusion Fluorouracil/Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) ("FOLFOX-4") With/Without Intravenous Bevacizumab (Q2W) as First-line Treatment for Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  12/11/2015
Clinical Research Facility
mi
from
Greenbrae, CA
A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer
A 2x2 Factorial Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) ("XELOX") With/Without Intravenous Bevacizumab (Q3W) Versus Bolus and Continuous Infusion Fluorouracil/Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) ("FOLFOX-4") With/Without Intravenous Bevacizumab (Q2W) as First-line Treatment for Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 12/11/2015
Clinical Research Facility
mi
from
Greenbrae, CA
Click here to add this to my saved trials
A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer
A 2x2 Factorial Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) ("XELOX") With/Without Intravenous Bevacizumab (Q3W) Versus Bolus and Continuous Infusion Fluorouracil/Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) ("FOLFOX-4") With/Without Intravenous Bevacizumab (Q2W) as First-line Treatment for Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  12/11/2015
Clinical Research Facility
mi
from
Los Angeles, CA
A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer
A 2x2 Factorial Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) ("XELOX") With/Without Intravenous Bevacizumab (Q3W) Versus Bolus and Continuous Infusion Fluorouracil/Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) ("FOLFOX-4") With/Without Intravenous Bevacizumab (Q2W) as First-line Treatment for Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 12/11/2015
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer
A 2x2 Factorial Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) ("XELOX") With/Without Intravenous Bevacizumab (Q3W) Versus Bolus and Continuous Infusion Fluorouracil/Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) ("FOLFOX-4") With/Without Intravenous Bevacizumab (Q2W) as First-line Treatment for Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  12/11/2015
Clinical Research Facility
mi
from
Orange, CA
A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer
A 2x2 Factorial Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) ("XELOX") With/Without Intravenous Bevacizumab (Q3W) Versus Bolus and Continuous Infusion Fluorouracil/Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) ("FOLFOX-4") With/Without Intravenous Bevacizumab (Q2W) as First-line Treatment for Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 12/11/2015
Clinical Research Facility
mi
from
Orange, CA
Click here to add this to my saved trials
A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer
A 2x2 Factorial Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) ("XELOX") With/Without Intravenous Bevacizumab (Q3W) Versus Bolus and Continuous Infusion Fluorouracil/Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) ("FOLFOX-4") With/Without Intravenous Bevacizumab (Q2W) as First-line Treatment for Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  12/11/2015
Clinical Research Facility
mi
from
Palo Alto, CA
A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer
A 2x2 Factorial Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) ("XELOX") With/Without Intravenous Bevacizumab (Q3W) Versus Bolus and Continuous Infusion Fluorouracil/Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) ("FOLFOX-4") With/Without Intravenous Bevacizumab (Q2W) as First-line Treatment for Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 12/11/2015
Clinical Research Facility
mi
from
Palo Alto, CA
Click here to add this to my saved trials
A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer
A 2x2 Factorial Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) ("XELOX") With/Without Intravenous Bevacizumab (Q3W) Versus Bolus and Continuous Infusion Fluorouracil/Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) ("FOLFOX-4") With/Without Intravenous Bevacizumab (Q2W) as First-line Treatment for Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  12/11/2015
Clinical Research Facility
mi
from
San Diego, CA
A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer
A 2x2 Factorial Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) ("XELOX") With/Without Intravenous Bevacizumab (Q3W) Versus Bolus and Continuous Infusion Fluorouracil/Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) ("FOLFOX-4") With/Without Intravenous Bevacizumab (Q2W) as First-line Treatment for Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 12/11/2015
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer
A 2x2 Factorial Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) ("XELOX") With/Without Intravenous Bevacizumab (Q3W) Versus Bolus and Continuous Infusion Fluorouracil/Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) ("FOLFOX-4") With/Without Intravenous Bevacizumab (Q2W) as First-line Treatment for Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  12/11/2015
Clinical Research Facility
mi
from
Norwich, CT
A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer
A 2x2 Factorial Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) ("XELOX") With/Without Intravenous Bevacizumab (Q3W) Versus Bolus and Continuous Infusion Fluorouracil/Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) ("FOLFOX-4") With/Without Intravenous Bevacizumab (Q2W) as First-line Treatment for Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 12/11/2015
Clinical Research Facility
mi
from
Norwich, CT
Click here to add this to my saved trials
A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer
A 2x2 Factorial Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) ("XELOX") With/Without Intravenous Bevacizumab (Q3W) Versus Bolus and Continuous Infusion Fluorouracil/Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) ("FOLFOX-4") With/Without Intravenous Bevacizumab (Q2W) as First-line Treatment for Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  12/11/2015
Clinical Research Facility
mi
from
Waterbury, CT
A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer
A 2x2 Factorial Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) ("XELOX") With/Without Intravenous Bevacizumab (Q3W) Versus Bolus and Continuous Infusion Fluorouracil/Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) ("FOLFOX-4") With/Without Intravenous Bevacizumab (Q2W) as First-line Treatment for Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 12/11/2015
Clinical Research Facility
mi
from
Waterbury, CT
Click here to add this to my saved trials
A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer
A 2x2 Factorial Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) ("XELOX") With/Without Intravenous Bevacizumab (Q3W) Versus Bolus and Continuous Infusion Fluorouracil/Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) ("FOLFOX-4") With/Without Intravenous Bevacizumab (Q2W) as First-line Treatment for Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  12/11/2015
Clinical Research Facility
mi
from
Boca Raton, FL
A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer
A 2x2 Factorial Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) ("XELOX") With/Without Intravenous Bevacizumab (Q3W) Versus Bolus and Continuous Infusion Fluorouracil/Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) ("FOLFOX-4") With/Without Intravenous Bevacizumab (Q2W) as First-line Treatment for Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 12/11/2015
Clinical Research Facility
mi
from
Boca Raton, FL
Click here to add this to my saved trials
A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer
A 2x2 Factorial Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) ("XELOX") With/Without Intravenous Bevacizumab (Q3W) Versus Bolus and Continuous Infusion Fluorouracil/Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) ("FOLFOX-4") With/Without Intravenous Bevacizumab (Q2W) as First-line Treatment for Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  12/11/2015
Clinical Research Facility
mi
from
Gainesville, FL
A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer
A 2x2 Factorial Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) ("XELOX") With/Without Intravenous Bevacizumab (Q3W) Versus Bolus and Continuous Infusion Fluorouracil/Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) ("FOLFOX-4") With/Without Intravenous Bevacizumab (Q2W) as First-line Treatment for Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 12/11/2015
Clinical Research Facility
mi
from
Gainesville, FL
Click here to add this to my saved trials
A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer
A 2x2 Factorial Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) ("XELOX") With/Without Intravenous Bevacizumab (Q3W) Versus Bolus and Continuous Infusion Fluorouracil/Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) ("FOLFOX-4") With/Without Intravenous Bevacizumab (Q2W) as First-line Treatment for Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  12/11/2015
Clinical Research Facility
mi
from
Jacksonville, FL
A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer
A 2x2 Factorial Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) ("XELOX") With/Without Intravenous Bevacizumab (Q3W) Versus Bolus and Continuous Infusion Fluorouracil/Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) ("FOLFOX-4") With/Without Intravenous Bevacizumab (Q2W) as First-line Treatment for Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 12/11/2015
Clinical Research Facility
mi
from
Jacksonville, FL
Click here to add this to my saved trials
A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer
A 2x2 Factorial Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) ("XELOX") With/Without Intravenous Bevacizumab (Q3W) Versus Bolus and Continuous Infusion Fluorouracil/Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) ("FOLFOX-4") With/Without Intravenous Bevacizumab (Q2W) as First-line Treatment for Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  12/11/2015
Clinical Research Facility
mi
from
New Port Richey, FL
A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer
A 2x2 Factorial Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) ("XELOX") With/Without Intravenous Bevacizumab (Q3W) Versus Bolus and Continuous Infusion Fluorouracil/Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) ("FOLFOX-4") With/Without Intravenous Bevacizumab (Q2W) as First-line Treatment for Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 12/11/2015
Clinical Research Facility
mi
from
New Port Richey, FL
Click here to add this to my saved trials